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Summary
The gene encoding AIB1, an estrogen receptor coactivator, is amplified in a subset of human breast cancers. Here we
show that overexpression of AIB1 in transgenic mice (AIB1-tg) leads to mammary hypertrophy, hyperplasia, abnormal
postweaning involution, and the development of malignant mammary tumors. Tumors are also increased in other organs,
including the pituitary and uterus. AIB1 overexpression increases mammary IGF-I mRNA and serum IGF-I protein levels.
In addition, IGF-I receptor and downstream signaling molecules are activated in primary mammary epithelial cells and
mammary tumor cells derived from AIB1-tg mice. Knockdown of AIB1 expression in cultured AIB1-tg mammary tumor
cells leads to reduced IGF-I mRNA levels and increased apoptosis, suggesting that an autocrine IGF-I loop underlies the
mechanism of AIB1-induced oncogenesis.
Introduction factors. For example, AIB1 can enhance transcription mediated
by STAT and NF-B (Torchia et al., 1997) and can reverse NF-
B-mediated inhibition of GR-activated genes (Werbajh et al.,AIB1 was cloned from a region of chromosome 20q11-13 fre-
quently found amplified in human breast and ovarian carcino- 2000).
Mice with a null mutation for the mouse homolog of AIB1,mas (Anzick et al., 1997). AIB1 is a member of the p160 family
of nuclear receptor coactivators (Halachmi et al., 1994), which p/CIP, are dwarfed and show impaired morphogenesis of the
mammary ductal system (Xu et al., 2000). This contrasts withalso includes SRC-1 and SRC-2. These proteins significantly
increase hormone-induced transcription mediated by nuclear the minimal effect of SRC-1 deletion on the mammary gland
(Xu et al., 1998) and suggests that AIB1 may be a nuclearreceptors, such as estrogen receptor (ER), progesterone recep-
tor (PR), thyroid hormone receptor (TR), glucocorticoid receptor receptor coactivator critical for mammary gland development.
Thus far, AIB1 is the only p160 nuclear coactivator that has(GR), and retinoic acid receptor (RAR), when overexpressed in
the presence of ligand (reviewed in Glass and Rosenfeld, 2000; been linked to cancer. AIB1 mRNA levels were found to be
increased in up to 60% of human breast tumors (Anzick et al.,McKenna et al., 1999). Recently, we have shown that the recruit-
ment of the p160 coactivators to the ER is a dynamic process 1997), and AIB1 protein levels were reported to be higher in
breast tumor sections as compared to normal breast tissue (Listsufficient for gene activation as well as cell cycle progression
(Shang et al., 2000). et al., 2001). AIB1 was also found to be amplified in hepatocellu-
lar carcinoma (HCC) (Wang et al., 2002), and in primary gastricAIB1 function can be regulated by upstream signaling path-
ways, such as MAPK and IB kinase (IKK), thus conveying cancers (Sakakura et al., 2000). In normal tissue, AIB1 is widely
expressed with particularly high levels in testis, mammary gland,growth factor and proliferation signals to the estrogen receptor
(Font de Mora and Brown, 2000; Wu et al., 2002). AIB1 has also uterus, pituitary, heart, lung, liver, skeletal muscle, and brain
(Chen et al., 1997; Takeshita et al., 1997; Torchia et al., 1997;been shown to function in a hormone receptor-independent
fashion to coactivate other p300/CBP associated transcription Suen et al., 1998).
S I G N I F I C A N C E
AIB1, an estrogen receptor coactivator, has been implicated as a causal factor in human breast cancer, as its gene is amplified
and/or overexpressed in a significant number of cases. We have tested this directly by making transgenic mice expressing AIB1 in the
mammary gland. These mice develop mammary hyperplasia and mammary carcinomas. In addition, we find that AIB1 overexpression
leads to increased levels of the growth factor IGF-I, suggesting that its mechanism of action involves the establishment of an autocrine
IGF-I loop. This breast cancer model demonstrates that AIB1 is indeed an oncogene, and provides evidence that supports the
development of targeted therapies that interfere with IGF-I signaling as an approach to the treatment of tumors dependent on AIB1.
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The connection between AIB1 overexpression and the ER showed that the strongest expression of AIB1 occurs in epithe-
lial cells. Again, AIB1-tg mice consistently showed higher lev-status of breast tumors is still controversial. While one study
found that AIB1 overexpression correlated with ER and pro- els of AIB1 plus p/CIP expression as compared with wt animals
during different stages of mammary gland development (Fig-gesterone receptor (PR) expression in breast tumors and with
tumor size (Bautista et al., 1998), two other studies found that ure 1E).
AIB1 overexpression occurred more frequently in ER- and PR-
negative tumors and correlated with high levels of HER2/neu Increased size of mammary gland, starting
at 4 weeks of ageand p53 proteins (Bouras et al., 2001; Osborne et al., 2003).
The latter studies suggest that AIB1 might correlate with the The sizes of virgin AIB1-tg mammary glands were measured as
whole mounts and were found to be 30% to 40% larger asmore aggressive, HER2/neu-positive tumor phenotype, and that
it might be involved in tamoxifen resistance. compared to wt mice (Figure 2A). The increased size of the
mammary gland was already apparent at puberty (4 weeks ofWhile these studies indicate that AIB1 is frequently overex-
pressed in mammary tumors, we are not aware of any direct age). The increased mammary gland size in AIB1-tg mice
seemed to be not only due to an increased number of epithelialevidence demonstrating a functional role of AIB1 in mammary
tumor formation. To address this issue, we directed AIB1 ex- cells but also due to an increased size of each individual cell.
pression to the mammary epithelium of mice. AIB1-tg mice
displayed abnormal mammary gland development and devel- Hyperplasia and accelerated differentiation
of mammary gland in AIB1-tg mice during pregnancyoped mammary adenocarcinomas and a variety of other tumors
with high frequency. Furthermore, AIB1-tg mice and tumors Whole-mount mammary glands from AIB1-tg mice at 2 weeks
of pregnancy showed more extensive lobuloalveolar develop-showed increased IGF-I levels and increased activation of the
IGF-IR/PI3K/AKT pathway. Our data demonstrate that AIB1 is ment, in contrast to pregnant wt animals. Moreover, mammary
glands from AIB1-tg pregnant mice showed a more extensivesufficient to cause the formation of mammary carcinomas and
other tumors, and thus is able to act as an oncogene. degree of ductal branching as compared to wt mice (not shown).
Histological sections of paraffin-embedded mammary glands
of AIB1-tg mice at 1 day postpartum revealed a disorganizedResults
epithelium with respect to the columnar arrangement of a normal
mammary epithelium (Figure 2B, top and bottom left panels).Establishment of AIB1 tg mice and analysis
of transgene expression Animals from all founder lines showed this phenotype with high
penetrance. In spite of the abnormal structure of the mammaryWe generated 13 lines of transgenic mice expressing a human
AIB1 cDNA gene under the transcriptional control of the mouse gland at this stage, AIB1-tg mice were able to nurse their pups
normally.mammary tumor virus (MMTV) long terminal repeat (LTR) pro-
moter/enhancer. Seven lines were then selected to generate
homozygous females. AIB1 mRNA expression of the seven Delayed involution in AIB1-tg mice
Hematoxylin and eosin (H&E)-stained sections at day 4 afterAIB1-tg lines was analyzed. Mammary glands from mature, vir-
gin mice (7 weeks) showed consistently high levels of AIB1 initiation of involution showed that the mammary alveolar struc-
tures from wt mice had started to collapse, and numerous apo-expression in all 7 founder lines, with lines D3 and D5 showing
the highest and D6 showing the lowest expression (Figure 1A). ptotic bodies were apparent in the luminal cells. In contrast, in
mammary glands from AIB1-tg mice, the alveoli had not yetPrimers used were specific for AIB1 and did not amplify the
endogenous murine AIB1 (p/CIP) mRNA. Next, we tested a begun to collapse (Figure 2B, 4d inv. panels). At day 14 of
involution, wt mammary glands were largely remodeled andvariety of organs for endogenous p/CIP and tg-AIB1 mRNA
expression using quantitative real-time PCR and determined resembled those of early pregnancy. In contrast, mammary
glands from AIB1-tg mice were still undergoing involution, asthe increase of transgene over wt expression. The organs were
derived from at least 10 different mice from 3 different lines. was apparent from the collapsing alveolar structures and the
disorganization of the gland (Figure 2B, 14d inv. panels). AfterThe highest fold increase of AIB1/pCIP expression was found
in the mammary gland (7.6-fold), followed by the pituitary (5.2- 21 days of involution, wt mammary glands were completely
remodeled, resembling the prepregnant state, while ducts fromfold), lung and uterus (3.3-fold each), liver (3.1-fold) and ovaries
(2.8-fold) (Figure 1B). Endogenous p/CIP mRNA levels were not AIB1-tg mammary glands failed to remodel. Instead, they re-
mained hypercellular, became dilated, and filled with secretionsaltered in the AIB1-tg mice as compared with wt (data not
shown). (Figure 2B, 21d inv. panels). These abnormalities persisted for
at least several months following weaning.Next we analyzed AIB1 mRNA levels during mammary gland
development in the 3 different AIB1-tg lines and compared them
to endogenous p/CIP mRNA levels of wt mice by quantitative Analysis of cell growth, proliferation, and apoptosis
The size of an organ is determined by coordinated regulationPCR. We found AIB1 mRNA levels to be 2.5- to 8-fold higher
than p/CIP levels of wt mice, depending on the developmental of cell growth (increase in cell size), cell proliferation (increase
in cell number), and cell death (apoptosis) (Conlon and Raff,stage (Figure 1C). Protein expression was established by West-
ern blots and immunohistochemistry, using an AIB1 antibody 1999). To determine the reasons behind the increased mammary
gland size and hyperplasia observed in the AIB1-tg mice, wethat detects both human AIB1 and mouse p/CIP. In Western
blots, AIB1-tg mammary glands taken from virgin animals, 1 analyzed cell size, cell number, proliferation, and apoptosis in
mammary gland epithelial cells of wt and AIB1-tg mice.day postpartum, or 4 days after onset of involution showed
significantly higher AIB1 plus p/CIP levels as compared to sam- The size of the epithelial cells was measured in mammary
glands from mice at day 1 postpartum, when we observed theples from wt animals (Figure 1D). Immunohistochemical analysis
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Figure 1. Expression pattern of the AIB1 transgene in mammary glands and different organs at different stages of development
A: AIB1 mRNA levels in different tg lines were determined by RT-PCR of total RNA from mammary glands of wt and tg mice, using primers specific for human
AIB1.
B: AIB1 and endogenous p/CIP mRNA levels were determined in different organs of tg animals using real-time PCR with primers specific for p/CIP or AIB1.
Results were normalized with GAPDH and averaged for 5 different experiments. The fold increase of tg over wt expression is indicated on top of each bar.
C: Real-time PCR analysis of ectopic AIB1 and endogenous p/CIP mRNA was performed on total RNA from wt and tg mammary glands at the indicated
stages of development. p/CIP levels were determined in samples from wt mice, AIB1 levels in samples from tg mice. Experiments were performed in
duplicates and repeated at least three times. Results were normalized with GAPDH.
D: Western blot analysis was performed to determine the combined protein levels of AIB1 and p/CIP in mammary glands from wt and AIB1 mice, at the
indicated stages of development. Blots were reprobed with an anti-calnexin antibody to normalize for loading differences.
E: Immunohistochemical analysis was performed on sections of paraffin-embedded mammary glands from wt and tg animals. Sections were stained with
a rabbit anti-human AIB1 primary antibody, developed with Vectastain ABC kit, and counterstained with hematoxylin. For the negative control, the primary
antibody was omitted. W, week; d, day; v, virgin; ppt, postpartum; inv, involution.
greatest difference in size between wt and AIB1-tg mammary Analysis of serum levels of prolactin, luteinizing
gland epithelial cells (Figure 3A). The average luminal epithelial hormone, and growth hormone
cell diameter from AIB1-tg mice was 2.0-fold  0.2 (SD) larger In the course of this study, several mice developed pituitary
than that of wt mice (Figure 3B). To quantify the ductal epithelial tumors (see below). To examine the possibility that a change
hyperplasia observed after onset of involution (see, for example, in serum levels of pituitary hormones, such as prolactin (PRL),
Figure 1E), we quantified epithelial cells at 21 days after initiation luteinizing hormone (LH), or growth hormone (GH), was poten-
of involution. The epithelial cell number per area in the AIB1-tg tially responsible for the observed mammary gland phenotype,
mammary gland was determined to be 2.5-fold higher than that serum levels of these hormones were determined by radioimmu-
of wt animals (data not shown). BrdU analysis was performed
noassay (RIA) (Fedele et al., 2002). Serum levels from a total of
on sections of mammary glands at 2 weeks of pregnancy, the
70 mice were examined, including wt and AIB1-tg animals, bothstage of the maximal rate of epithelial cell proliferation. As shown
male and female animals, and several animals with pituitaryin Figures 3C and 3D, the fraction of BrdU positive epithelial
tumors. In all animals, serum levels of GH, PRL, and LH werecells was50% higher in the AIB1-tg mammary gland as com-
within the physiological range and thus did not differ significantlypared to the wt. TUNEL assays were performed on sections of
between wt and AIB1-tg animals as a consequence of AIB1mammary glands from day 4 after the onset of involution. As
overexpression (data not shown). Furthermore, animals wereshown in Figure 3E, the number of epithelial cells undergoing
fertile and cycled normally. Therefore, the observed AIB1-tgapoptosis in the mammary glands of AIB1-tg mice was 33%
lower as compared to wt mice. phenotype of lobuloalveolar hyperplasia and accelerated differ-
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unusual squamous cysts with central keratin debris were also
frequently observed in AIB1-tg mice (Figures 4D–4F).
Tumor incidence and analysis of tumor phenotype
In order to evaluate tumor incidence and age of onset, 203 tg
mice from the seven founder lines were analyzed, and 100 mice
were maintained for aging. Tumors developed in mice from all
lines, and there was no correlation between tumor type and
founder line. Mice were grouped by status as nulliparous (virgin)
and parous (one or more litters). From the aging group of mice,
76 animals carrying 1 or several tumors were detected as early
as 9 months of age, with an average latency of 16 months
(Figure 5). In a total of 145 tumors, we detected a large number of
mammary gland adenocarcinomas, pituitary adenomas, uterine
leiomyosarcomas, and lung adenocarcinomas. Several other
tumor types occurred with lesser frequency (Table 1).
In comparison, cohorts of age-matched wt controls (a total
of 105 animals) only displayed 5 tumors (3 lung and 2 pituitary
tumors) by 19–22 months of age. Significantly, none of the
control animals developed mammary gland tumors. Both the
rate of total tumor formation and the incidence of mammary
gland tumors alone were significantly different between AIB1-tg
and wt control animals (p0.0007 and p 0.0001, respectively;
Figures 5A and 5B). Thus, tumor formation in our model was
strictly dependent on the transgene and could not be explained
by the spontaneous formation of pituitary adenomas and associ-
ated mammary tumors reported for the strain of FVB/NCr mice
(Wakefield et al., 2003). Furthermore, in our model, there was
no correlation between the formation of pituitary adenomas and
Figure 2. Increased mammary gland size, increased numbers of mammary
mammary tumors. Only a subgroup of mice developing pituitarygland epithelial cells, and disorganized mammary gland structure in AIB1-
adenomas showed mammary gland carcinomas, and vice versa,tg mice
not all mice carrying mammary carcinomas developed pituitaryA: Whole-mount photography of mammary glands from wt (top panels)
and AIB1-tg mice (bottom panels) of 4-week-old (left panels) or 10-week- adenomas. Interestingly, the frequency and latency of mammary
old (right panels) virgin mice. The respective length of the mammary glands tumorigenesis in nulliparous AIB1-tg mice was not significantly
in cm is indicated. different from that of the parous studied mice (Figure 5D and log-
B: Histological analysis of H&E-stained mammary gland sections at different
rank test; data not shown), suggesting that the tumorigenicity ofstages of development. Top panels show wt mammary glands. Bottom
AIB1 is independent of the reproductive history of the mice.panels show AIB1-tg mammary glands.
The histopathology of the mammary tumors revealed an
incidence of several subtypes of adenocarcinomas (Figure 5E,
top panels), including acinar, ductal, solid comedo type, and
papillary adenocarcinoma as defined by the Annapolis Histo-entiation does not appear to result from differences in the levels
pathology Conference (Cardiff et al., 2000). Most of the tumorsof circulating PRL, GH, or LH.
were invasive, as determined by the presence of nests and
cords of tumor cells infiltrating the adjacent tissue like skeletal
Histopathological analysis of early proliferative lesions
muscle or brain (as in the case of some pituitary tumors). Further-
Mammary glands of AIB1-tg mice showed numerous hyperplas- more, several adenocarcinomas were metastatic, showing tu-
tic, noninvasive focal lesions, observed as early as 5 months mor formation composed by the same original cell type in lung,
of age. The hyperplastic lesions were multilayered and often bones, and kidney (not shown).
appeared to be originating from ducts (Figure 4A). Solid lesions
generally contained larger foci with dense masses of atypical Analysis of AIB1 and ER expression in mammary
cells organized in nodular sheets (Figure 4B). This phenotype gland tumors
developed in AIB1-tg mice independent of their reproductive We analyzed the AIB1 and ER expression status of mammary
history and without hormonal manipulation. The phenotype of gland tumors from AIB1-tg mice by immunohistochemistry,
these lesions is consistent with a premalignant phenotype, re- Western blot, and quantitative PCR. By immunohistochemistry,
ferred to as mammary intraepithelial neoplasia (MIN) (Cardiff et approximately 85% of the tumors were ER-positive with nuclear
al., 2000). In addition to the hyperplastic structures, alterations staining, while 15% of the mammary gland tumors were ER-
of the lobular architecture were frequently observed in virgin negative (Figure 5E). Tumors were considered ER-positive when
and resting mammary glands, including differentiating alveoli more than 1% of the tumor cells showed ER staining regardless
and secretory alveolar structures (Figure 4C). Ductal ectasia and the intensity of staining. An example of a tumor scored as ER-
increased connective tissue was a particularly common feature negative tumor can be seen in Figure 5E. In this tumor, the
malignant cells are ER-negative, while areas of normal epithelialin AIB1-tg mice (Figures 4B and 4C). Squamous metaplasia and
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Figure 3. Increased cell growth, increased prolif-
eration, and delayed apoptosis in AIB1-tg mam-
mary glands
A: The average cell size was determined from
wt and AIB1-tg mice at 1 day postpartum by
measuring the maximum diameter of epithelial
cells in histological cross-sections.
B: For each mammary gland, a total of 500 cells
in 10 different fields were measured and the av-
erage diameter calculated. Similar results were
obtained from at least 5 mammary glands.
C and D: Determination of the number of prolifer-
ating cells by BrdU incorporation. Wt (left panels)
and AIB1-tg (right panels) mice at 2 weeks of
pregnancy were injected with BrdU. Cross-sec-
tions of isolated mammary glands were stained
with H&E (upper panel) or with an anti BrdU anti-
body followed by counterstaining with hematox-
ylin (lower panel) (C). The number of BrdU-posi-
tive cells was counted in 10 fields per slide.
Graphed results represent the average of 3 inde-
pendent assays (D).
E: Determination of the number of apoptotic
cells by TUNEL assay. After TUNEL labeling, the
number of dUTP-positive cells was determined in
mammary glands from mice 4 days after initia-
tion of involution. Graphed results represent the
average of 3 independent assays.
Figure 4. Histological analysis by H&E staining reveals premalignant phenotype of AIB1-tg mammary glands
A: Example of persistent hyperplasia and ductal ectasia in a nulliparous AIB1-tg mouse.
B: Example of a solid lesion with dense masses of atypical cells surrounded by connective tissue.
C: Secreting alveolar structures are surrounded by stromal tissue in the mammary gland of nulliparous tg mice.
D–F: Squamous metaplasia and unusual squamous cysts, shown at different magnifications.
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Figure 5. Tumor-free survival of mice and histo-
pathological and immunohistochemical analysis
of mammary adenocarcinomas
A and B: Kaplan-Meier analysis of tumor-free sur-
vival of wt versus AIB1-tg mice. A: Tumors of all
origins were taken into account. B: Only mam-
mary tumors were taken into account.
C and D: Kaplan-Meier analysis of tumor-free sur-
vival of nulliparous versus parous AIB1-tg mice,
accounting for all tumors (C) or mammary tu-
mors only (D). The median of tumor incidence
for all tumors was 16 months.
E: Paraffin-embedded sections of tumors were
stained with H&E (top panels), anti-AIB1 antibody
(middle panels), or anti-ER antibody (lower
panels). Tumors represented lobular, microaci-
nar, and comedo type. The arrow in the lower
left panel indicates ER staining of normal cells.
Tg lines from which the tumors were obtained
are indicated below.
cells demonstrate normal ER staining. Interestingly, while AIB1 is activated in mammary glands and tumors of AIB1-tg mice by
probing Western blots with antibodies for phosphorylated formswas strongly expressed in normal, hyperplastic, and malignant
epithelial cells, its localization, while nuclear in the normal epithe- of a comprehensive set of members of this signaling pathway,
including pIGF-IR (tyr1131), pAKT (ser473), pTSC (thr1462),lium, was often cytoplasmic in tumor cells (Figures 1E and 5E).
pmTOR (ser2448), peIF4G (ser1108), pp70S6K (thr389), and
pS6RP (ser235/236).Activation of the IGF-R/PI3K/AKT/mTOR pathway
and GSK3 in mammary glands and tumors First, we analyzed extracts from whole mammary glands
at different stages of development (Figure 6A). Differences infrom AIB1-tg mice
Increased cell and organ sizes have been linked to upregulation p70S6K and S6RP phosphorylation between wt and AIB1-tg
mammary glands were already apparent at 7 weeks of age.of the PI3 kinase/AKT/mTOR pathway (Patel et al., 2002; Leev-
ers et al., 1996). We therefore determined whether this pathway Phosphorylation of these proteins increased dramatically in the
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We next wanted to examine whether the increased levelsTable 1. AIB1 tumor incidence
of these phosphoisoforms were indeed occurring in AIB1-over-
Tumor type Number
expressing epithelial cells or whether there was any involvement
Mammary gland adenocarcinomas 48 of stroma cells in this upregulation. We generated primary epi-
ER () mammary gland tumors 40 thelial cell cultures (ECC) from virgin wt and AIB1-tg mammary
ER () mammary gland tumors 8
glands of 10-week-old mice and examined protein extracts. AllPituitary adenomas 42
Uterine leiomyosarcomas 18 phosphoisoforms examined were found to be increased be-
Lung adenocarcinomas 18 tween 3- and 20-fold in ECC from AIB1-tg mammary glands
Fibrosarcomas 6 (Figure 6B). In contrast, the nonphosphorylated forms of the
Skin papillomas 3
proteins examined remained largely unchanged, with the excep-Ovarian teratomas 3
Lymphomas 2 tion of mTOR, which also showed a strong increase in expres-
Osteomacrophage sarcomas (liver) 2 sion in the AIB1-tg samples. In addition to these factors, we
Adrenocortical tumors (kidney) 2 examined another target of AKT, GSK3 (ser9), and one of
Squamous cell carcinoma (skin) 1
its downstream effectors, cyclin D1. Among other functions,
Total tumors 145 GSK3 is implicated in the activation of -catenin. Phosphoryla-
Animals bearing tumors 76
tion of Ser 9 of GSK3, the substrate of AKT, was stronglyTotal aging animals 100
increased in AIB1-tg ECC samples, while total GSK3 levels
remained constant. Furthermore, cyclin D1 levels were dramati-
cally increased and p-catenin (ser45) levels decreased in the
AIB1-tg ECC (Figure 6B and data not shown). This p-catenincourse of pregnancy, in both wt and AIB1-tg animals and in
is targeted for degradation by the proteasome, while unphos-parallel with AIB1 levels. While p-S6RP levels decreased in
phorylated -catenin accumulates and translocates to the nu-AIB1-tg and wt animals during involution, p-p85S6K levels re-
mained high in AIB1-tg animals and only declined in wt animals. cleus, leading to the activation of target genes. We also analyzed
Figure 6. AIB1 activates the PI3K/AKT/mTOR pathway and its downstream effectors
A: Western blot analysis of mammary gland extracts from different stages of development. Mouse embryo fibroblasts from PTEN null mutants (/) and
wt mice (/) served as controls for the activation of the PI3K/AKT pathway.
B: Western blot analysis of 40 g protein extracts from ECC of 10-week-old wt and AIB1-tg mice, using phospho-antibodies (p) and total levels of the
indicated proteins. Signal intensities were determined by densitometry and normalized using a calnexin antibody.
C: Analysis of IGF-I serum levels by IP-Western blot (left panel) and IGF-I mRNA levels in primary ECC by quantitative RT-PCR (right panel). 250 l of serum
from 10-week-old AIB1-tg or wt mice was subjected to immunoprecipitation and subsequent Western blot analysis using IGF-I antibody. Band intensities
were determined by densitometry and averaged over 3 independent experiments (left panel). Total RNA from primary ECC derived from 10 tg and 10 wt
control mice was quantified by real-time PCR, using IGF-I specific primers.
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protein extracts from primary mammary tumors and tumor- Discussion
derived cell lines. All samples analyzed showed similarly high
Despite the circumstantial evidence linking AIB1 to humanlevels of the phosphorylated forms of IGF-IR, p70S6K, and
breast cancer, the role of AIB1 in the etiology of mammarypS6RP (data not shown).
carcinomas has not yet been rigorously established. Our studySince IGF-IR was found to be activated in AIB1 tumors as
now demonstrates the potential of the AIB1 gene by itself towell as in mammary glands and primary ECC of AIB1-tg mice,
trigger a uniform premalignant phenotype in mammary epithelialwe wanted to determine whether AIB1 might activate IGF-IR
cells that progresses with high frequency to mammary adeno-through an increased production of IGF-I. We therefore mea-
carcinomas.sured IGF-I serum levels and levels of IGF-I protein and mRNA
Expression of the AIB1 transgene in our study was controlledin the mammary gland. We found circulating IGF-I levels to be
by the MMTV LTR, the most frequently used promoter in tgincreased by2.5-fold in AIB1-tg as compared with wt animals.
models of mouse mammary cancer (Cardiff et al., 2000). The
A similar increase was detected for IGF-I mRNA levels in AIB1-
MMTV LTR has been shown to be active throughout mammary
Tg ECC (Figure 6C). gland development, leading to particularly high expression dur-
ing pregnancy and lactation (Gunzburg and Salmons, 1992).
PR levels are downregulated in tg mammary glands Consistent with these reports, we found that AIB1 transgene
and ECC despite increased ER levels expression was already apparent in mature, virgin animals and
It has been shown that increased IGF-I levels lead to lower persisted throughout cycles of pregnancy. However, MMTV LTR
progesterone receptor (PR) mRNA and protein levels in breast activity is not restricted to the mammary gland, but has also
been reported for salivary glands, liver, lung, lymphoid cells,cancer cells (Cui et al., 2003a, 2003b). Consistent with these
spleen, seminal vesicles, and testes, albeit at lower levels (Choidata, we found PR levels to be lower in AIB1-tg mice, as early
et al., 1987; King and Corley, 1990). In our study, we detectedas 10 weeks of age (as determined by Western blot, data not
particularly high AIB1 expression levels in the lung, pituitary,shown). In contrast, ER levels were found to be persistently
and uterus, consistent with the development of tumors in thesehigher in AIB1-tg as compared to wt mammary glands. Thus,
organs.PR expression is regulated independently from ER expression
The somewhat different pattern of MMTV-LTR activity andin AIB1-tg.
AIB1 transgene expression reported here is not unexpected.
First, the AIB1 transgene can function as a nuclear receptor
AIB1 silencing demonstrates its necessity in IGF-I coactivator for GR and PR (Liao et al., 2002), and glucocorticoids
expression and cell survival and progestins are the major activators of the hormone response
The phenotypic changes observed in AIB1-tg mice might be elements present in the MMTV LTR (Gunzburg and Salmons,
triggered by AIB1 in an indirect manner through early events in 1992). Second, AIB1 has been shown to function as an NF-B
the life of an AIB1-tg mouse. In this case, AIB1 might no longer coactivator (Torchia et al., 1997) and is able to counteract the
play a direct role in the maintenance of a hyperplastic or tumoro- NF-B-mediated repression of GR (Scheinman et al., 1995).
genic phenotype of the mammary gland. Alternatively, AIB1 may Thus, we would expect an MMTV-driven AIB1 transgene to
continue to play a critical role after the phenotypic changes undergo a significant degree of positive autoregulation. To our
occur. To distinguish between these possibilities, we knocked knowledge, MMTV LTR activity in the pituitary has not been
previously reported, but it is not unexpected, given that MMTVdown AIB1 expression in cell lines derived from AIB1-tg prema-
expression is strongly activated by prolactin, a hormone pro-lignant mammary glands and tumors using siRNA, and deter-
duced in the pituitary (Munoz and Bolander, 1989; Gunzburgmined the phenotypic changes of these cells. Western blot dem-
and Salmons, 1992). The somewhat expanded activity of theonstrated that transfection with a specific AIB1 siRNA led to
MMTV LTR reported in this study enabled the unexpected dis-knockdown of AIB1 by 	80% at protein level as compared to
covery that AIB1 can mediate tumorigenicity in organs othera nonspecific control siRNA (Figure 7A). In order to determine
than the mammary gland, most notably pituitary, lung, andwhether continued AIB1 expression is required for the increased
uterus, and in tissues other than epithelial cells.level of IGF-I expressed in AIB1-tg ECC and tumor cells, we
The mammary glands of a large majority of transgenic ani-assayed the level of IGF-1 mRNA expressed in these cells fol-
mals from all seven founder lines showed a uniform premalig-lowing knockdown of AIB1. The levels of IGF-I mRNA were
nant phenotype. This phenotype consisted of an increased sizedecreased by 66% in AIB1-tg ECC and 50% in an AIB1-tg
of mammary glands and mammary gland epithelial cells, a failure
derived mammary tumor cell line 48 hr after AIB1-specific siRNA
to undergo complete involution, and the presence of squamous
transfection (Figure 7B). These results demonstrate that contin- metaplasia, persistent hyperplasia, and continuously secreting
ued AIB1 expression is required to drive the high level of IGF-I glands (galactorrhea). We further showed that the persistent
expression found in these cells. Furthermore, FACS analysis hyperplasia was due to a combination of increased cellular pro-
revealed that 12 3% of the AIB1 siRNA transfected cells were liferation and evasion of apoptosis.
in the sub-GI fraction (Figure 7D), as compared to 0% for the The AIB1-induced hyperplastic lesions observed appeared
mock transfected and 1% for control nonspecific siRNA trans- to be mainly alveolar lesions. The high-grade lesions showed
fected cells. TUNEL assay confirmed the marked increase in several layers of epithelium, pleomorphism of nuclei, and an
apoptosis in AIB1 siRNA transfected cells (Figure 7E). These increase in mitotic figures, which are all hallmarks of mammary
data demonstrate that AIB1 is not only sufficient to induce mam- intraepithelial neoplasia (MIN). MIN lesions represent a morpho-
mary tumors, but also necessary for continued mammary tumor logical intermediate between normal tissue and cancerous tis-
sue and are considered to have a high potential for malignancycell survival.
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Figure 7. Silencing of AIB1 expression leads to re-
duction of IGF-I levels and to apoptosis
A and B: Primary ECC and tumor cell lines (TCL1,
TCL4, TCL110) from AIB1-tgs were transfected
with siRNA oligos for AIB1 (siAIB1), luciferase (si-
LUC), or no RNA (mock) as controls. Cells were
harvested 48 hr after transfection. Downregula-
tion of AIB1 expression was confirmed by real-
time PCR (A) and Western blot (B).
C: IGF-I mRNA levels were determined by real-
time PCR.
D: The percentage of apoptotic cells was deter-
mined by flow cytometry, after staining of cells
with propidium iodide.
E: TUNEL assay showing apoptotic cells.
(Cardiff et al., 2000). This is also true for the lesions detected we next wanted to determine the mechanism(s) of AIB1 oncoge-
nicity. Several features of the observed phenotype suggestedin our model, given that 50% of all aging animals developed
one or more mammary tumors. Taken together, the mammary to us an involvement of the PI3K/AKT/mTOR pathway and its
downstream targets (Bai et al., 2000; Mills et al., 2001; Hanahangland phenotype developed in AIB1-tg mice suggests that AIB1
is sufficient to trigger initial steps of tumor formation that ulti- and Weinberg, 2000). First, mammary glands and epithelial cells
in AIB1-tgs showed an increased size as compared to wt mice,mately lead to invasive carcinoma.
The AIB1-tg mice in this study showed a dramatic tumor and the PI3K/AKT pathway has been implicated in the regulation
of organ and cell size (Gingras et al., 2001).incidence, with76% of aging animals developing one or more
tumors. In addition to mammary tumors, tumors were found in Second, the histopathology of the premalignant lesions and
mammary adenocarcinomas showed similarity to mouse mod-several other organs, including pituitary, lung, and uterus. All
tumors developed in a focal and stochastic fashion. The fre- els targeting members of the PI3K/AKT/mTOR signaling path-
way. The unusual squamous metaplasia reported here stronglyquency of mammary tumors and the stochastic appearance
of tumors are comparable to many other tumor models using resembles the lesions found in -catenin tg mice (Miyoshi et
al., 2002). The precocious lobulo-alveolar development of theMMTV-driven oncogenes as transgenes (Cardiff and Muller,
1993). However, in contrast to other mouse models using AIB1-tg mammary glands resembles that of mice engineered
with a conditional loss of PTEN in the mammary gland (Li etMMTV-driven oncogenes, the tumors observed in AIB1-tg mice
were surprisingly heterogeneous in type and organ distribution. al., 2002). The adenosquamous carcinomas and papillary and
cribriform adenocarcinomas found in AIB1 transgenics haveThis could be due to the somewhat altered expression pattern
of the MMTV-AIB1 transgene as compared to other MMTV- also been reported for cyclin D1 transgenics (Wang et al., 1994).
Cyclin D1, -catenin, and PTEN are all part of the PI3K/AKT/driven transgenes (as discussed above).
Mammary adenocarcinomas in our study did not show a mTOR signaling pathway, a pathway increasingly linked to can-
cer (Scheid and Woodgett, 2001; Vivanco and Sawyers, 2002;distinct “signature phenotype,” but were of several subtypes,
as defined by the Annapolis Panel (Cardiff et al., 2000), including Surmacz, 2003).
Our results demonstrate that the ectopic expression of AIB1acinar (also found in wnt-1 tgs), cribriform (as in c-myc tgs),
and papillary (as in wnt-2 tg). In addition to mammary adenocar- in the mammary gland leads to activation of several members
of the IGF-IR/PI3K/AKT/mTOR pathway in primary mammarycinomas that are frequently found with other MMTV-driven on-
cogenes, tumors originating from cells other than epithelial cells epithelial cell cultures, in whole mammary glands, and in primary
mammary tumors. We also demonstrate a direct correlationwere identified, including leiomyosarcomas, fibrosarcomas, ter-
atomas, and papillomas. Consistent with the notion that AIB1 between AIB1 expression levels and PI3K/AKT activation, since
mouse strains or samples with higher AIB1 levels show in-was the causative agent of these tumors, all tumors analyzed
were AIB1-positive, and high levels of AIB1 expression were also creased activation of the pathway. Interestingly, we also found
that other mouse models with activated PI3K/AKT pathway,detected in the respective tumor-free organ. Together, these
findings raise the possibility that AIB1 may be involved in a namely TSC null mutants (not shown) and PTEN null mutants
(Figure 7A), in turn show overexpression of pCIP (murine AIB1),much wider range of human tumors than previously thought.
After having established that AIB1 is a potent oncogene, suggesting that the activation of the PI3K/AKT pathway in
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Experimental proceduresTSC/ and PTEN/ cells activates expression of the (endoge-
nous) p/CIP gene. These findings indicate not only that AIB1 is
Generation of AIB1-tg micesufficient to activate PI3K/AKT signaling, but also that it may
A 4.8 kb fragment of the human AIB1 cDNA (Anzick et al., 1997), kindly
be a target of this pathway through an autoregulatory feedback provided by Paul S. Meltzer, was isolated from the pcDNA3.1 AIB1 plasmid
loop. using ApaI and NotI restriction enzymes. A NotI site was added at the ApaI
In an attempt to account for the increased IGF-IR activation site. The fragment was cloned into the NotI site of the pTLMTV-SV40 vector
(Muller et al., 1990), kindly provided by Dr. Philip Leder. To derive tg mice,in AIB1-tg mice, we further demonstrate an increase of IGF-I
the pTLMTVB-hAIB1 NheI/SalI fragment was microinjected into fertilizedserum levels and IGF-I mRNA levels in mammary gland epithelial
eggs derived from FVB/N mice as described (Muller et al., 1988). Mice werecells. These results indicate that AIB1 can modulate IGF-IR
maintained on an FVB/N background using stock mice from Taconic Farms,signaling in mammary epithelial cells in an endocrine and auto-
Inc. Integration of the transgene into the offspring genome was assessed
crine manner. Consistent with our findings, mice homozygous by Southern blot and PCR analysis.
for a p/CIP null mutant display decreased serum levels of IGF-I
and show dwarfism (Wang et al., 2000). Thus, regulation of IGF-I RT-PCR and real-time PCR analysis
levels is not only a feature of the overexpressed, human AIB1 Total RNA from homogenized tissue samples was extracted by Trizol (In-
vitrogen), reverse transcribed, and amplified by PCR using the followinggene product, but can also be mediated by the endogenous
primers: AIB1 sense: 5
GCTTGACATCCTTTGACTGG3
; AIB1 antisense:gene.
5
TAAGATTGGCAGATATCAGCTCAGC3
; actin sense: 5
GGGTATGGAATCIt has been previously shown that in liver cells, the IGF-I
CTGTGGCA3
; actin antisense: 5
-TGGACAGTGAGGCCAAGATG3
. All
promoter can be induced by estradiol. While this promoter does
real-time PCR reactions were performed using SYBR Green PCR Core Re-
not contain a classical estrogen response element, ER has agents kit (PE-Applied-Biosystem) and an ABI Prism 7700 sequence Detector
been shown to act through an AP1 site (Umayahara et al., 1994). System. Primers used for real-time PCR were: AIB1 sense, 5
GCGGCGAGTT
Since AIB1 acts as an ER coactivator, these findings suggest TCCGATTTA3
; AIB1 antisense, 5
GCTCCCGTCTCCGTTTTTCT3
; p/CIP
sense 5
ATTTGCTGAACAGTGGACTCC3
; p/CIP antisense 5
TTCGCCTAa direct mechanism for AIB1-mediated regulation of IGF-I levels
GTCCACTCATCCTG3
. IGF1 sense 5
GCTATGGCTCCAGCATTCG3
; IGF1and activation of the IGF-IR/PI3K/AKT/mTOR pathway. A direct
antisense 5
GCTCCGGAAGCAACACTCA3
; mouse GAPDH primers wereinvolvement of AIB1 in the regulation of IGF expression is further
obtained from Applied Biosystems.
demonstrated by our experiments showing that downregulation
of AIB1 expression levels by RNA interference leads to reduc- Small interfering RNA transfection
tions in IGF-I mRNA levels and a marked increase in apoptosis 100 nM of small interfering RNA (siRNA) duplex oligonucleotides (Dhar-
in primary epithelial and tumor cells. In addition, these results macon) targeting AIB1 mRNA (5
AGACUCCUUAGGACCGCUUdTdT3
) was
transfected using Lipofectamine 2000 (Invitrogen) according to the manufac-indicate that the survival of tumor cells from AIB1-tgs remains
turer’s instructions. Cells were harvested 48 hr after transfection.dependent on high-level AIB1 expression and therefore argue
against the possibility that AIB1 might be only required for the
Whole mounts, histology, and immunohistochemistry analysisinduction of the premalignant phenotype observed in AIB1-tg
Mammary glands were dissected, mounted on glass slides, and stained
animals but not for the generation of subsequent tumors.
as described at http://mammary.nih.gov/tools/histological/Histology/index.
Of note, serum IGF-I levels and IGF-IR signaling have been html. Tissues were fixed overnight in 10% neutralized buffered formalin and
implicated in the etiology of breast cancer (LeRoith and Roberts, embedded in paraffin by standard procedures. Sections of 4 m thickness
2003), and IGF-IR signals synergize with ER action in the regu- were stained with H&E or processed for immunohistochemistry analysis
following antigen retrieval. Polyclonal ER (1:3000) (Santa Cruz) or polyclonallation of proliferation and apoptosis (Dupont et al., 2000). IGF-I
AIB1 (1:200) (produced in our laboratory) were routinely used. Slides weretgs have also been reported to display a high frequency (50%)
counterstained with hematoxylin.of mammary tumors, albeit at a later onset (24 month) than in
our study (Hadsell and Abdel-Fattah, 2001). Together, our data
BrdU labeling and TUNEL assays
demonstrate a further connection between mammary tumor
Four hours before sacrifice, wt and tg mice at 2 weeks of pregnancy were
formation and the actions of ER and IGF-I, as the estrogen injected with 20 l/g of body weight of BrdU (Sigma). Cross-sections were
receptor coactivator AIB1 is critically involved in the regulation stained with an anti BrdU antibody (BD Bioscience) and counterstained with
of autocrine and systemic IGF-I levels. hematoxylin. The number of BrdU-positive cells in wt and tg samples was
counted in 10 fields per slide, under 20 magnification. Final results repre-At this point, we cannot rule out that other receptors and/
sent the average of 3 independently performed assays. TUNEL assays (On-or signaling pathways are also activated by AIB1, especially
cogene Research Products) were performed on cross-sections of mammaryin non-mammary gland tumors and ER negative mammary
glands obtained from animals at day 4 of involution, according to the manu-tumors, which await further investigation.
facturer’s instructions.
Taken together, our data establish that AIB1 can function
as an oncogene and that the AIB1-tg mice produced in this Immunoblot analysis
study provide a useful model to study the progression from a Polyclonal rabbit anti-AIB1 antibody was produced in the lab, and used for
premalignant mammary gland phenotype to malignant carcino- Western blots and immunostaining. Goat anti-mouse IGF-I was obtained
from Chemicon, polyclonal ER rabbit (MC-20) from Santa Cruz. Polyclonalmas. Furthermore, our data imply that the AIB1 gene amplifica-
anti-Calnexin (Stressgen) was used as control for protein loading. All thetion and overexpression observed in human breast cancer is a
antibodies for the PI3 kinase pathway were purchased from Cell Signalingcausal factor in the formation and progression of this disease
Technology. Isolated mammary gland, tumor samples, or cells were lysedand thus a potential drug target. Lastly, the AIB1-tg model will
in ice-cold RIPA buffer including protease inhibitor cocktail (Roche). Lysates
allow the dissection of the ER-dependent and ER-inde- were centrifuged at 14,000 RPM for 15 min. 70 g of protein was separated
pendent functions of AIB1 in mammary tumorigenesis, and on 4%–15% SDS-PAGE gradient gel (Bio-Rad) and transferred to nitrocellu-
points to a potential involvement of AIB1 in tumors of other lose membranes. Blots were probed with the antibodies indicated and devel-
oped with Renaissance chemiluminescent detection system (Perkin-Elmer).organs that are not under estrogen control.
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ACTR is a novel histone acetyltransferase and forms a multimeric activationSerum hormone measurements
complex with P/CAF and CBP/p300. Cell 90, 569–580.Serum concentrations of prolactin (PRL), growth hormone (GH), and luteiniz-
ing hormone (LH) were measured using mouse PRL, GH, and LH radioimmu-
Choi, Y.W., Henrard, D., Lee, I., and Ross, S.R. (1987). The mouse mammary
noassays by Dr. A.F. Parlow (National Hormone & Peptide Program Harbor- tumor virus long terminal repeat directs expression in epithelial and lymphoid
UCLA Medical Center), as described (Fedele et al., 2002). cells of different tissues in tg mice. J. Virol. 61, 3013–3019.
Conlon, I., and Raff, M. (1999). Size control in animal development. Cell 96,Primary cell cultures
235–244.Tumor cells were isolated as described (Medina and Kittrell, 2000). Primary
cultures of mouse mammary epithelium were prepared as described (Regi- Cui, X., Lazard, Z., Zhang, P., Hopp, T.A., and Lee, A.V. (2003a). Progester-
nato et al., 2003). one crosstalks with insulin-like growth factor signaling in breast cancer cells
via induction of insulin receptor substrate-2. Oncogene 22, 6937–6941.
Statistical analysis
Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G.B., and Lee,Means and standard deviations have been estimated for continuous vari-
A.V. (2003b). Insulin-like growth factor-I inhibits progesterone receptor ex-ables. Tumor-free survival was calculated using the product-limit method
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tial indicator of growth factor activity in breast cancer. Mol. Endocrinol. 17,were ascertained using a two-sided log-rank test (Peto and Peto, 1972).
575–588.
Differences between the two populations were considered significant at
confidence levels greater than 95% (p 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